Literature DB >> 11083650

Presence of variations in ribosomal protein L16 corresponding to susceptibility of enterococci to oligosaccharides (Avilamycin and evernimicin).

F M Aarestrup1, L B Jensen.   

Abstract

Fragments (414 bp) of the gene-encoding ribosomal protein L16 from Enterococcus faecium and Enterococcus faecalis that were resistant and susceptible to the oligosaccharide antibiotics avilamycin and evernimicin (SCH 27899) were sequenced and compared. The susceptible E. faecalis and E. faecium isolates had sequences that were similar to those of the type strains. All resistant E. faecalis isolates contained the same base pair variation [CGT (Arg-56) --> CAT (His-56)]. The same variation and two additional variations [ATC (Ile-52) --> ACC (Thr-52) and ATC (Ile-52) --> AGC (Ser-52)] were found in the resistant E. faecium isolates. This study indicated that resistance to the oligosaccharides in enterococci is associated with variations in the ribosomal protein L16.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083650      PMCID: PMC90215          DOI: 10.1128/AAC.44.12.3425-3427.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin.

Authors:  C Urban; N Mariano; K Mosinka-Snipas; C Wadee; T Chahrour; J J Rahal
Journal:  J Antimicrob Chemother       Date:  1996-02       Impact factor: 5.790

2.  Molecular analysis of Tn1546 in Enterococcus faecium isolated from animals and humans.

Authors:  L B Jensen; P Ahrens; L Dons; R N Jones; A M Hammerum; F M Aarestrup
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.

Authors:  M A Schouten; A Voss; J A Hoogkamp-Korstanje
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 4.  Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

Authors:  R N Jones; D E Low; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1999-02       Impact factor: 2.803

5.  Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group.

Authors:  S A Marshall; R N Jones; M E Erwin
Journal:  Diagn Microbiol Infect Dis       Date:  1999-01       Impact factor: 2.803

6.  Surveillance of antimicrobial resistance in bacteria isolated from food animals to antimicrobial growth promoters and related therapeutic agents in Denmark.

Authors:  F M Aarestrup; F Bager; N E Jensen; M Madsen; A Meyling; H C Wegener
Journal:  APMIS       Date:  1998-06       Impact factor: 3.205

7.  Major trends in the microbial etiology of nosocomial infection.

Authors:  D R Schaberg; D H Culver; R P Gaynes
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

8.  Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin.

Authors:  F M Aarestrup
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

Review 9.  Hospital-acquired infections: diseases with increasingly limited therapies.

Authors:  M N Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Everninomicin, a new oligosaccharide antibiotic: its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity.

Authors:  S Nakashio; H Iwasawa; F Y Dun; K Kanemitsu; J Shimada
Journal:  Drugs Exp Clin Res       Date:  1995
View more
  12 in total

1.  Mutations in ribosomal protein L16 and in 23S rRNA in Enterococcus strains for which evernimicin MICs differ.

Authors:  Myriam Zarazaga; Carmen Tenorio; Rosa Del Campo; Fernanda Ruiz-Larrea; Carmen Torres
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Interaction of avilamycin with ribosomes and resistance caused by mutations in 23S rRNA.

Authors:  Christine B Kofoed; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Avilamycin and evernimicin induce structural changes in rProteins uL16 and CTC that enhance the inhibition of A-site tRNA binding.

Authors:  Miri Krupkin; Itai Wekselman; Donna Matzov; Zohar Eyal; Yael Diskin Posner; Haim Rozenberg; Ella Zimmerman; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-19       Impact factor: 11.205

4.  Differential effects of thiopeptide and orthosomycin antibiotics on translational GTPases.

Authors:  Aleksandra Mikolajka; Hanqing Liu; Yuanwei Chen; Agata L Starosta; Viter Márquez; Marina Ivanova; Barry S Cooperman; Daniel N Wilson
Journal:  Chem Biol       Date:  2011-05-27

5.  A novel site of antibiotic action in the ribosome: interaction of evernimicin with the large ribosomal subunit.

Authors:  L Belova; T Tenson; L Xiong; P M McNicholas; A S Mankin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  Effects of mutations in ribosomal protein L16 on susceptibility and accumulation of evernimicin.

Authors:  P M McNicholas; P A Mann; D J Najarian; L Miesel; R S Hare; T A Black
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Combined antimicrobial resistance in Enterococcus faecium isolated from chickens.

Authors:  Odile Petsaris; Fabien Miszczak; Mireille Gicquel-Bruneau; Agnès Perrin-Guyomard; Florence Humbert; Pascal Sanders; Roland Leclercq
Journal:  Appl Environ Microbiol       Date:  2005-05       Impact factor: 4.792

Review 8.  Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria.

Authors:  Patrick Butaye; Luc A Devriese; Freddy Haesebrouck
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

9.  Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome.

Authors:  Stefan Arenz; Manuel F Juette; Michael Graf; Fabian Nguyen; Paul Huter; Yury S Polikanov; Scott C Blanchard; Daniel N Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-21       Impact factor: 11.205

10.  Incidence of high-level evernimicin resistance in Enterococcus faecium among food animals and humans.

Authors:  Frank Møller Aarestrup; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.